nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—CA5A—female reproductive system—urinary bladder cancer	0.0158	0.111	CbGeAlD
Metolazone—CA7—renal system—urinary bladder cancer	0.0132	0.0924	CbGeAlD
Metolazone—SLC12A3—renal system—urinary bladder cancer	0.0129	0.0905	CbGeAlD
Metolazone—CA5B—prostate gland—urinary bladder cancer	0.0113	0.079	CbGeAlD
Metolazone—SLC12A3—female reproductive system—urinary bladder cancer	0.0103	0.0725	CbGeAlD
Metolazone—CA9—female reproductive system—urinary bladder cancer	0.00926	0.065	CbGeAlD
Metolazone—CA12—renal system—urinary bladder cancer	0.00855	0.06	CbGeAlD
Metolazone—CA4—prostate gland—urinary bladder cancer	0.00777	0.0545	CbGeAlD
Metolazone—CA5B—urethra—urinary bladder cancer	0.00754	0.0529	CbGeAlD
Metolazone—CA12—female reproductive system—urinary bladder cancer	0.00685	0.0481	CbGeAlD
Metolazone—CA4—seminal vesicle—urinary bladder cancer	0.00657	0.0461	CbGeAlD
Metolazone—CA5B—female reproductive system—urinary bladder cancer	0.00614	0.0431	CbGeAlD
Metolazone—CA5B—vagina—urinary bladder cancer	0.00556	0.039	CbGeAlD
Metolazone—CA4—renal system—urinary bladder cancer	0.00529	0.0372	CbGeAlD
Metolazone—CA4—urethra—urinary bladder cancer	0.0052	0.0365	CbGeAlD
Metolazone—CA4—female reproductive system—urinary bladder cancer	0.00424	0.0298	CbGeAlD
Metolazone—CA5B—lymph node—urinary bladder cancer	0.00359	0.0252	CbGeAlD
Metolazone—CA4—lymph node—urinary bladder cancer	0.00248	0.0174	CbGeAlD
Metolazone—CA9—Cellular response to hypoxia—VHL—urinary bladder cancer	0.0014	0.0938	CbGpPWpGaD
Metolazone—Pancreatitis—Methotrexate—urinary bladder cancer	0.00123	0.00146	CcSEcCtD
Metolazone—Discomfort—Etoposide—urinary bladder cancer	0.00122	0.00145	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00122	0.00145	CcSEcCtD
Metolazone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00122	0.00145	CcSEcCtD
Metolazone—Somnolence—Fluorouracil—urinary bladder cancer	0.00122	0.00144	CcSEcCtD
Metolazone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00121	0.00143	CcSEcCtD
Metolazone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.0012	0.00143	CcSEcCtD
Metolazone—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.0012	0.00142	CcSEcCtD
Metolazone—Fatigue—Gemcitabine—urinary bladder cancer	0.0012	0.00142	CcSEcCtD
Metolazone—Constipation—Gemcitabine—urinary bladder cancer	0.00119	0.00141	CcSEcCtD
Metolazone—Pain—Gemcitabine—urinary bladder cancer	0.00119	0.00141	CcSEcCtD
Metolazone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00119	0.00141	CcSEcCtD
Metolazone—Asthenia—Thiotepa—urinary bladder cancer	0.00119	0.00141	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00118	0.0014	CcSEcCtD
Metolazone—Abdominal distension—Epirubicin—urinary bladder cancer	0.00118	0.0014	CcSEcCtD
Metolazone—Pruritus—Thiotepa—urinary bladder cancer	0.00117	0.00139	CcSEcCtD
Metolazone—Pain—Fluorouracil—urinary bladder cancer	0.00117	0.00139	CcSEcCtD
Metolazone—Paraesthesia—Cisplatin—urinary bladder cancer	0.00116	0.00138	CcSEcCtD
Metolazone—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00116	0.00138	CcSEcCtD
Metolazone—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00115	0.00137	CcSEcCtD
Metolazone—Dry skin—Doxorubicin—urinary bladder cancer	0.00115	0.00136	CcSEcCtD
Metolazone—Pancreatitis—Epirubicin—urinary bladder cancer	0.00115	0.00136	CcSEcCtD
Metolazone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00115	0.00136	CcSEcCtD
Metolazone—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.00114	0.00136	CcSEcCtD
Metolazone—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00114	0.00135	CcSEcCtD
Metolazone—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00114	0.00135	CcSEcCtD
Metolazone—Anorexia—Etoposide—urinary bladder cancer	0.00113	0.00134	CcSEcCtD
Metolazone—Diarrhoea—Thiotepa—urinary bladder cancer	0.00113	0.00134	CcSEcCtD
Metolazone—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00113	0.00134	CcSEcCtD
Metolazone—Decreased appetite—Cisplatin—urinary bladder cancer	0.00113	0.00134	CcSEcCtD
Metolazone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00113	0.00134	CcSEcCtD
Metolazone—Drowsiness—Methotrexate—urinary bladder cancer	0.00111	0.00132	CcSEcCtD
Metolazone—Pain—Cisplatin—urinary bladder cancer	0.00111	0.00132	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00111	0.00131	CcSEcCtD
Metolazone—Dizziness—Thiotepa—urinary bladder cancer	0.00109	0.0013	CcSEcCtD
Metolazone—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00109	0.00129	CcSEcCtD
Metolazone—Urticaria—Fluorouracil—urinary bladder cancer	0.00109	0.00129	CcSEcCtD
Metolazone—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00107	0.00127	CcSEcCtD
Metolazone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00107	0.00127	CcSEcCtD
Metolazone—Paraesthesia—Etoposide—urinary bladder cancer	0.00107	0.00127	CcSEcCtD
Metolazone—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00106	0.00126	CcSEcCtD
Metolazone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00106	0.00125	CcSEcCtD
Metolazone—Somnolence—Etoposide—urinary bladder cancer	0.00106	0.00125	CcSEcCtD
Metolazone—Epistaxis—Methotrexate—urinary bladder cancer	0.00105	0.00125	CcSEcCtD
Metolazone—Vomiting—Thiotepa—urinary bladder cancer	0.00105	0.00125	CcSEcCtD
Metolazone—Drowsiness—Epirubicin—urinary bladder cancer	0.00104	0.00124	CcSEcCtD
Metolazone—Rash—Thiotepa—urinary bladder cancer	0.00104	0.00124	CcSEcCtD
Metolazone—Dermatitis—Thiotepa—urinary bladder cancer	0.00104	0.00124	CcSEcCtD
Metolazone—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00104	0.00123	CcSEcCtD
Metolazone—Headache—Thiotepa—urinary bladder cancer	0.00104	0.00123	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00103	0.00123	CcSEcCtD
Metolazone—Decreased appetite—Etoposide—urinary bladder cancer	0.00103	0.00122	CcSEcCtD
Metolazone—Fatigue—Etoposide—urinary bladder cancer	0.00102	0.00121	CcSEcCtD
Metolazone—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00102	0.00121	CcSEcCtD
Metolazone—Pain—Etoposide—urinary bladder cancer	0.00102	0.0012	CcSEcCtD
Metolazone—Constipation—Etoposide—urinary bladder cancer	0.00102	0.0012	CcSEcCtD
Metolazone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00101	0.0012	CcSEcCtD
Metolazone—Hepatitis—Methotrexate—urinary bladder cancer	0.001	0.00119	CcSEcCtD
Metolazone—Asthenia—Gemcitabine—urinary bladder cancer	0.000998	0.00118	CcSEcCtD
Metolazone—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000988	0.00117	CcSEcCtD
Metolazone—Epistaxis—Epirubicin—urinary bladder cancer	0.000984	0.00117	CcSEcCtD
Metolazone—Pruritus—Gemcitabine—urinary bladder cancer	0.000984	0.00117	CcSEcCtD
Metolazone—Nausea—Thiotepa—urinary bladder cancer	0.000982	0.00117	CcSEcCtD
Metolazone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000978	0.00116	CcSEcCtD
Metolazone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000977	0.00116	CcSEcCtD
Metolazone—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000974	0.00116	CcSEcCtD
Metolazone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000971	0.00115	CcSEcCtD
Metolazone—Pruritus—Fluorouracil—urinary bladder cancer	0.000967	0.00115	CcSEcCtD
Metolazone—Drowsiness—Doxorubicin—urinary bladder cancer	0.000965	0.00115	CcSEcCtD
Metolazone—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000957	0.00114	CcSEcCtD
Metolazone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000955	0.00113	CcSEcCtD
Metolazone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000951	0.00113	CcSEcCtD
Metolazone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000946	0.00112	CcSEcCtD
Metolazone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000946	0.00112	CcSEcCtD
Metolazone—Urticaria—Etoposide—urinary bladder cancer	0.000943	0.00112	CcSEcCtD
Metolazone—Abdominal pain—Etoposide—urinary bladder cancer	0.000938	0.00111	CcSEcCtD
Metolazone—Hepatitis—Epirubicin—urinary bladder cancer	0.000937	0.00111	CcSEcCtD
Metolazone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000935	0.00111	CcSEcCtD
Metolazone—Tinnitus—Methotrexate—urinary bladder cancer	0.000933	0.00111	CcSEcCtD
Metolazone—Asthenia—Cisplatin—urinary bladder cancer	0.00093	0.0011	CcSEcCtD
Metolazone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000911	0.00108	CcSEcCtD
Metolazone—Dizziness—Fluorouracil—urinary bladder cancer	0.000904	0.00107	CcSEcCtD
Metolazone—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000901	0.00107	CcSEcCtD
Metolazone—Chills—Methotrexate—urinary bladder cancer	0.000898	0.00107	CcSEcCtD
Metolazone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000887	0.00105	CcSEcCtD
Metolazone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000886	0.00105	CcSEcCtD
Metolazone—Vomiting—Gemcitabine—urinary bladder cancer	0.000884	0.00105	CcSEcCtD
Metolazone—Rash—Gemcitabine—urinary bladder cancer	0.000877	0.00104	CcSEcCtD
Metolazone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000876	0.00104	CcSEcCtD
Metolazone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000875	0.00104	CcSEcCtD
Metolazone—Tinnitus—Epirubicin—urinary bladder cancer	0.000873	0.00104	CcSEcCtD
Metolazone—Headache—Gemcitabine—urinary bladder cancer	0.000871	0.00103	CcSEcCtD
Metolazone—Vomiting—Fluorouracil—urinary bladder cancer	0.000869	0.00103	CcSEcCtD
Metolazone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000867	0.00103	CcSEcCtD
Metolazone—Rash—Fluorouracil—urinary bladder cancer	0.000862	0.00102	CcSEcCtD
Metolazone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000861	0.00102	CcSEcCtD
Metolazone—Headache—Fluorouracil—urinary bladder cancer	0.000856	0.00102	CcSEcCtD
Metolazone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000853	0.00101	CcSEcCtD
Metolazone—Asthenia—Etoposide—urinary bladder cancer	0.000852	0.00101	CcSEcCtD
Metolazone—Back pain—Methotrexate—urinary bladder cancer	0.000843	0.001	CcSEcCtD
Metolazone—Chills—Epirubicin—urinary bladder cancer	0.00084	0.000997	CcSEcCtD
Metolazone—Pruritus—Etoposide—urinary bladder cancer	0.00084	0.000997	CcSEcCtD
Metolazone—Nausea—Gemcitabine—urinary bladder cancer	0.000826	0.00098	CcSEcCtD
Metolazone—Vomiting—Cisplatin—urinary bladder cancer	0.000824	0.000978	CcSEcCtD
Metolazone—Vision blurred—Methotrexate—urinary bladder cancer	0.000821	0.000975	CcSEcCtD
Metolazone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000819	0.000973	CcSEcCtD
Metolazone—Rash—Cisplatin—urinary bladder cancer	0.000817	0.00097	CcSEcCtD
Metolazone—Dermatitis—Cisplatin—urinary bladder cancer	0.000816	0.000969	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—CREBBP—urinary bladder cancer	0.000816	0.0547	CbGpPWpGaD
Metolazone—Diarrhoea—Etoposide—urinary bladder cancer	0.000812	0.000964	CcSEcCtD
Metolazone—Nausea—Fluorouracil—urinary bladder cancer	0.000812	0.000964	CcSEcCtD
Metolazone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000808	0.000959	CcSEcCtD
Metolazone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000808	0.000959	CcSEcCtD
Metolazone—Anaemia—Methotrexate—urinary bladder cancer	0.000805	0.000956	CcSEcCtD
Metolazone—Flatulence—Epirubicin—urinary bladder cancer	0.000803	0.000954	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—RBX1—urinary bladder cancer	0.000803	0.0539	CbGpPWpGaD
Metolazone—Tension—Epirubicin—urinary bladder cancer	0.0008	0.00095	CcSEcCtD
Metolazone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000798	0.000948	CcSEcCtD
Metolazone—Nervousness—Epirubicin—urinary bladder cancer	0.000792	0.00094	CcSEcCtD
Metolazone—Back pain—Epirubicin—urinary bladder cancer	0.000789	0.000936	CcSEcCtD
Metolazone—Malaise—Methotrexate—urinary bladder cancer	0.000786	0.000933	CcSEcCtD
Metolazone—Dizziness—Etoposide—urinary bladder cancer	0.000785	0.000932	CcSEcCtD
Metolazone—Muscle spasms—Epirubicin—urinary bladder cancer	0.000784	0.00093	CcSEcCtD
Metolazone—Vertigo—Methotrexate—urinary bladder cancer	0.000783	0.000929	CcSEcCtD
Metolazone—Leukopenia—Methotrexate—urinary bladder cancer	0.00078	0.000926	CcSEcCtD
Metolazone—Chills—Doxorubicin—urinary bladder cancer	0.000778	0.000923	CcSEcCtD
Metolazone—Nausea—Cisplatin—urinary bladder cancer	0.00077	0.000914	CcSEcCtD
Metolazone—Vision blurred—Epirubicin—urinary bladder cancer	0.000768	0.000912	CcSEcCtD
Metolazone—Cough—Methotrexate—urinary bladder cancer	0.00076	0.000902	CcSEcCtD
Metolazone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000757	0.000898	CcSEcCtD
Metolazone—Vomiting—Etoposide—urinary bladder cancer	0.000755	0.000896	CcSEcCtD
Metolazone—Anaemia—Epirubicin—urinary bladder cancer	0.000754	0.000894	CcSEcCtD
Metolazone—Agitation—Epirubicin—urinary bladder cancer	0.000749	0.000889	CcSEcCtD
Metolazone—Rash—Etoposide—urinary bladder cancer	0.000749	0.000888	CcSEcCtD
Metolazone—Dermatitis—Etoposide—urinary bladder cancer	0.000748	0.000888	CcSEcCtD
Metolazone—Headache—Etoposide—urinary bladder cancer	0.000744	0.000883	CcSEcCtD
Metolazone—Flatulence—Doxorubicin—urinary bladder cancer	0.000743	0.000882	CcSEcCtD
Metolazone—Arthralgia—Methotrexate—urinary bladder cancer	0.000742	0.00088	CcSEcCtD
Metolazone—Chest pain—Methotrexate—urinary bladder cancer	0.000742	0.00088	CcSEcCtD
Metolazone—Tension—Doxorubicin—urinary bladder cancer	0.00074	0.000879	CcSEcCtD
Metolazone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000739	0.000877	CcSEcCtD
Metolazone—Malaise—Epirubicin—urinary bladder cancer	0.000735	0.000873	CcSEcCtD
Metolazone—Discomfort—Methotrexate—urinary bladder cancer	0.000733	0.00087	CcSEcCtD
Metolazone—Nervousness—Doxorubicin—urinary bladder cancer	0.000733	0.00087	CcSEcCtD
Metolazone—Vertigo—Epirubicin—urinary bladder cancer	0.000733	0.000869	CcSEcCtD
Metolazone—Syncope—Epirubicin—urinary bladder cancer	0.000731	0.000868	CcSEcCtD
Metolazone—Leukopenia—Epirubicin—urinary bladder cancer	0.00073	0.000866	CcSEcCtD
Metolazone—Back pain—Doxorubicin—urinary bladder cancer	0.00073	0.000866	CcSEcCtD
Metolazone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000725	0.000861	CcSEcCtD
Metolazone—Palpitations—Epirubicin—urinary bladder cancer	0.000721	0.000855	CcSEcCtD
Metolazone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000717	0.000851	CcSEcCtD
Metolazone—Cough—Epirubicin—urinary bladder cancer	0.000712	0.000844	CcSEcCtD
Metolazone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000711	0.000844	CcSEcCtD
Metolazone—Nausea—Etoposide—urinary bladder cancer	0.000705	0.000837	CcSEcCtD
Metolazone—Hypertension—Epirubicin—urinary bladder cancer	0.000704	0.000835	CcSEcCtD
Metolazone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.0007	0.000831	CcSEcCtD
Metolazone—Anaemia—Doxorubicin—urinary bladder cancer	0.000697	0.000828	CcSEcCtD
Metolazone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000696	0.000826	CcSEcCtD
Metolazone—Arthralgia—Epirubicin—urinary bladder cancer	0.000694	0.000824	CcSEcCtD
Metolazone—Chest pain—Epirubicin—urinary bladder cancer	0.000694	0.000824	CcSEcCtD
Metolazone—Agitation—Doxorubicin—urinary bladder cancer	0.000693	0.000823	CcSEcCtD
Metolazone—Anxiety—Epirubicin—urinary bladder cancer	0.000692	0.000821	CcSEcCtD
Metolazone—Discomfort—Epirubicin—urinary bladder cancer	0.000686	0.000814	CcSEcCtD
Metolazone—Malaise—Doxorubicin—urinary bladder cancer	0.00068	0.000807	CcSEcCtD
Metolazone—Dry mouth—Epirubicin—urinary bladder cancer	0.000679	0.000806	CcSEcCtD
Metolazone—Vertigo—Doxorubicin—urinary bladder cancer	0.000678	0.000804	CcSEcCtD
Metolazone—Anorexia—Methotrexate—urinary bladder cancer	0.000678	0.000804	CcSEcCtD
Metolazone—Syncope—Doxorubicin—urinary bladder cancer	0.000677	0.000803	CcSEcCtD
Metolazone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000675	0.000802	CcSEcCtD
Metolazone—Palpitations—Doxorubicin—urinary bladder cancer	0.000667	0.000791	CcSEcCtD
Metolazone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000663	0.000787	CcSEcCtD
Metolazone—Cough—Doxorubicin—urinary bladder cancer	0.000658	0.000781	CcSEcCtD
Metolazone—Shock—Epirubicin—urinary bladder cancer	0.000655	0.000777	CcSEcCtD
Metolazone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000652	0.000773	CcSEcCtD
Metolazone—Hypertension—Doxorubicin—urinary bladder cancer	0.000651	0.000773	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000648	0.000769	CcSEcCtD
Metolazone—Insomnia—Methotrexate—urinary bladder cancer	0.000643	0.000763	CcSEcCtD
Metolazone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000642	0.000762	CcSEcCtD
Metolazone—Chest pain—Doxorubicin—urinary bladder cancer	0.000642	0.000762	CcSEcCtD
Metolazone—Anxiety—Doxorubicin—urinary bladder cancer	0.00064	0.00076	CcSEcCtD
Metolazone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000639	0.000758	CcSEcCtD
Metolazone—Discomfort—Doxorubicin—urinary bladder cancer	0.000635	0.000753	CcSEcCtD
Metolazone—Anorexia—Epirubicin—urinary bladder cancer	0.000634	0.000753	CcSEcCtD
Metolazone—Somnolence—Methotrexate—urinary bladder cancer	0.000632	0.00075	CcSEcCtD
Metolazone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000628	0.000746	CcSEcCtD
Metolazone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000626	0.000743	CcSEcCtD
Metolazone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000618	0.000734	CcSEcCtD
Metolazone—Fatigue—Methotrexate—urinary bladder cancer	0.000613	0.000728	CcSEcCtD
Metolazone—Pain—Methotrexate—urinary bladder cancer	0.000608	0.000722	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000606	0.00072	CcSEcCtD
Metolazone—Shock—Doxorubicin—urinary bladder cancer	0.000606	0.000719	CcSEcCtD
Metolazone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000603	0.000716	CcSEcCtD
Metolazone—Insomnia—Epirubicin—urinary bladder cancer	0.000602	0.000714	CcSEcCtD
Metolazone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000598	0.000709	CcSEcCtD
Metolazone—Somnolence—Epirubicin—urinary bladder cancer	0.000592	0.000702	CcSEcCtD
Metolazone—Anorexia—Doxorubicin—urinary bladder cancer	0.000587	0.000697	CcSEcCtD
Metolazone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000586	0.000695	CcSEcCtD
Metolazone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000586	0.000695	CcSEcCtD
Metolazone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000581	0.00069	CcSEcCtD
Metolazone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000578	0.000687	CcSEcCtD
Metolazone—Fatigue—Epirubicin—urinary bladder cancer	0.000574	0.000681	CcSEcCtD
Metolazone—Constipation—Epirubicin—urinary bladder cancer	0.000569	0.000675	CcSEcCtD
Metolazone—Pain—Epirubicin—urinary bladder cancer	0.000569	0.000675	CcSEcCtD
Metolazone—Urticaria—Methotrexate—urinary bladder cancer	0.000565	0.00067	CcSEcCtD
Metolazone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000562	0.000667	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000561	0.000666	CcSEcCtD
Metolazone—Insomnia—Doxorubicin—urinary bladder cancer	0.000557	0.000661	CcSEcCtD
Metolazone—CA9—Regulation of gene expression by Hypoxia-inducible Factor—EP300—urinary bladder cancer	0.000555	0.0373	CbGpPWpGaD
Metolazone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000553	0.000656	CcSEcCtD
Metolazone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000548	0.000651	CcSEcCtD
Metolazone—Somnolence—Doxorubicin—urinary bladder cancer	0.000547	0.00065	CcSEcCtD
Metolazone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000544	0.000646	CcSEcCtD
Metolazone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000542	0.000643	CcSEcCtD
Metolazone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000535	0.000635	CcSEcCtD
Metolazone—Fatigue—Doxorubicin—urinary bladder cancer	0.000531	0.00063	CcSEcCtD
Metolazone—Urticaria—Epirubicin—urinary bladder cancer	0.000529	0.000627	CcSEcCtD
Metolazone—Pain—Doxorubicin—urinary bladder cancer	0.000527	0.000625	CcSEcCtD
Metolazone—Constipation—Doxorubicin—urinary bladder cancer	0.000527	0.000625	CcSEcCtD
Metolazone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000526	0.000624	CcSEcCtD
Metolazone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000524	0.000622	CcSEcCtD
Metolazone—Asthenia—Methotrexate—urinary bladder cancer	0.00051	0.000606	CcSEcCtD
Metolazone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000507	0.000602	CcSEcCtD
Metolazone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000504	0.000598	CcSEcCtD
Metolazone—Pruritus—Methotrexate—urinary bladder cancer	0.000503	0.000597	CcSEcCtD
Metolazone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00049	0.000582	CcSEcCtD
Metolazone—Urticaria—Doxorubicin—urinary bladder cancer	0.000489	0.000581	CcSEcCtD
Metolazone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000487	0.000578	CcSEcCtD
Metolazone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000487	0.000577	CcSEcCtD
Metolazone—Asthenia—Epirubicin—urinary bladder cancer	0.000477	0.000567	CcSEcCtD
Metolazone—Pruritus—Epirubicin—urinary bladder cancer	0.000471	0.000559	CcSEcCtD
Metolazone—Dizziness—Methotrexate—urinary bladder cancer	0.00047	0.000558	CcSEcCtD
Metolazone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000455	0.00054	CcSEcCtD
Metolazone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000454	0.000538	CcSEcCtD
Metolazone—Vomiting—Methotrexate—urinary bladder cancer	0.000452	0.000537	CcSEcCtD
Metolazone—Rash—Methotrexate—urinary bladder cancer	0.000448	0.000532	CcSEcCtD
Metolazone—Dermatitis—Methotrexate—urinary bladder cancer	0.000448	0.000532	CcSEcCtD
Metolazone—Headache—Methotrexate—urinary bladder cancer	0.000445	0.000529	CcSEcCtD
Metolazone—Asthenia—Doxorubicin—urinary bladder cancer	0.000442	0.000524	CcSEcCtD
Metolazone—Dizziness—Epirubicin—urinary bladder cancer	0.00044	0.000522	CcSEcCtD
Metolazone—Pruritus—Doxorubicin—urinary bladder cancer	0.000436	0.000517	CcSEcCtD
Metolazone—SLC12A3—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000426	0.0286	CbGpPWpGaD
Metolazone—Vomiting—Epirubicin—urinary bladder cancer	0.000423	0.000502	CcSEcCtD
Metolazone—Nausea—Methotrexate—urinary bladder cancer	0.000422	0.000501	CcSEcCtD
Metolazone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000421	0.0005	CcSEcCtD
Metolazone—Rash—Epirubicin—urinary bladder cancer	0.00042	0.000498	CcSEcCtD
Metolazone—Dermatitis—Epirubicin—urinary bladder cancer	0.000419	0.000498	CcSEcCtD
Metolazone—Headache—Epirubicin—urinary bladder cancer	0.000417	0.000495	CcSEcCtD
Metolazone—Dizziness—Doxorubicin—urinary bladder cancer	0.000407	0.000483	CcSEcCtD
Metolazone—Nausea—Epirubicin—urinary bladder cancer	0.000395	0.000469	CcSEcCtD
Metolazone—Vomiting—Doxorubicin—urinary bladder cancer	0.000392	0.000465	CcSEcCtD
Metolazone—Rash—Doxorubicin—urinary bladder cancer	0.000388	0.000461	CcSEcCtD
Metolazone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000388	0.00046	CcSEcCtD
Metolazone—Headache—Doxorubicin—urinary bladder cancer	0.000386	0.000458	CcSEcCtD
Metolazone—Nausea—Doxorubicin—urinary bladder cancer	0.000366	0.000434	CcSEcCtD
Metolazone—CA9—Cellular response to hypoxia—CREBBP—urinary bladder cancer	0.00036	0.0242	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000354	0.0237	CbGpPWpGaD
Metolazone—CA9—Cellular response to hypoxia—EP300—urinary bladder cancer	0.000245	0.0165	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000216	0.0145	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—VHL—urinary bladder cancer	0.000212	0.0142	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000212	0.0142	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000166	0.0111	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000156	0.0105	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTZ1—urinary bladder cancer	0.000134	0.00897	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000128	0.00856	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTO2—urinary bladder cancer	0.000127	0.00851	CbGpPWpGaD
Metolazone—CA5A—Metabolism—NAT1—urinary bladder cancer	0.000127	0.00851	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTZ1—urinary bladder cancer	0.000125	0.00838	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTZ1—urinary bladder cancer	0.000125	0.00838	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—RBX1—urinary bladder cancer	0.000122	0.00817	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTO2—urinary bladder cancer	0.000118	0.00794	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTO2—urinary bladder cancer	0.000118	0.00794	CbGpPWpGaD
Metolazone—CA5B—Metabolism—NAT1—urinary bladder cancer	0.000118	0.00794	CbGpPWpGaD
Metolazone—CA7—Metabolism—NAT1—urinary bladder cancer	0.000118	0.00794	CbGpPWpGaD
Metolazone—CA5A—Metabolism—UGT2B7—urinary bladder cancer	0.000116	0.00778	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.00776	CbGpPWpGaD
Metolazone—CA9—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000113	0.00757	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.00736	CbGpPWpGaD
Metolazone—CA12—Metabolism—NAT1—urinary bladder cancer	0.00011	0.00736	CbGpPWpGaD
Metolazone—CA7—Metabolism—UGT2B7—urinary bladder cancer	0.000108	0.00726	CbGpPWpGaD
Metolazone—CA5B—Metabolism—UGT2B7—urinary bladder cancer	0.000108	0.00726	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CYP4B1—urinary bladder cancer	0.000104	0.00701	CbGpPWpGaD
Metolazone—CA12—Metabolism—UGT2B7—urinary bladder cancer	0.0001	0.00673	CbGpPWpGaD
Metolazone—CA5A—Metabolism—SLC19A1—urinary bladder cancer	9.86e-05	0.00662	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CYP4B1—urinary bladder cancer	9.75e-05	0.00654	CbGpPWpGaD
Metolazone—CA7—Metabolism—CYP4B1—urinary bladder cancer	9.75e-05	0.00654	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PRSS3—urinary bladder cancer	9.61e-05	0.00645	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTZ1—urinary bladder cancer	9.23e-05	0.00619	CbGpPWpGaD
Metolazone—CA7—Metabolism—SLC19A1—urinary bladder cancer	9.21e-05	0.00618	CbGpPWpGaD
Metolazone—CA5B—Metabolism—SLC19A1—urinary bladder cancer	9.21e-05	0.00618	CbGpPWpGaD
Metolazone—CA12—Metabolism—CYP4B1—urinary bladder cancer	9.03e-05	0.00606	CbGpPWpGaD
Metolazone—CA7—Metabolism—PRSS3—urinary bladder cancer	8.97e-05	0.00602	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PRSS3—urinary bladder cancer	8.97e-05	0.00602	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTO2—urinary bladder cancer	8.75e-05	0.00587	CbGpPWpGaD
Metolazone—CA4—Metabolism—NAT1—urinary bladder cancer	8.75e-05	0.00587	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—GSTP1—urinary bladder cancer	8.64e-05	0.00579	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.62e-05	0.00578	CbGpPWpGaD
Metolazone—CA12—Metabolism—SLC19A1—urinary bladder cancer	8.53e-05	0.00572	CbGpPWpGaD
Metolazone—CA12—Metabolism—PRSS3—urinary bladder cancer	8.31e-05	0.00558	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CCNE1—urinary bladder cancer	8.18e-05	0.00549	CbGpPWpGaD
Metolazone—CA4—Metabolism—UGT2B7—urinary bladder cancer	8e-05	0.00537	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—SOD2—urinary bladder cancer	7.97e-05	0.00535	CbGpPWpGaD
Metolazone—CA5A—Metabolism—TYMP—urinary bladder cancer	7.68e-05	0.00515	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—GPX1—urinary bladder cancer	7.6e-05	0.0051	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTZ1—urinary bladder cancer	7.45e-05	0.005	CbGpPWpGaD
Metolazone—CA4—Metabolism—CYP4B1—urinary bladder cancer	7.2e-05	0.00483	CbGpPWpGaD
Metolazone—CA5B—Metabolism—TYMP—urinary bladder cancer	7.17e-05	0.00481	CbGpPWpGaD
Metolazone—CA7—Metabolism—TYMP—urinary bladder cancer	7.17e-05	0.00481	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTO2—urinary bladder cancer	7.07e-05	0.00474	CbGpPWpGaD
Metolazone—CA9—Metabolism—NAT1—urinary bladder cancer	7.07e-05	0.00474	CbGpPWpGaD
Metolazone—CA5A—Metabolism—NAT2—urinary bladder cancer	6.95e-05	0.00466	CbGpPWpGaD
Metolazone—CA4—Metabolism—SLC19A1—urinary bladder cancer	6.8e-05	0.00456	CbGpPWpGaD
Metolazone—CA12—Metabolism—TYMP—urinary bladder cancer	6.64e-05	0.00446	CbGpPWpGaD
Metolazone—CA4—Metabolism—PRSS3—urinary bladder cancer	6.63e-05	0.00445	CbGpPWpGaD
Metolazone—CA7—Metabolism—NAT2—urinary bladder cancer	6.49e-05	0.00435	CbGpPWpGaD
Metolazone—CA5B—Metabolism—NAT2—urinary bladder cancer	6.49e-05	0.00435	CbGpPWpGaD
Metolazone—CA9—Metabolism—UGT2B7—urinary bladder cancer	6.46e-05	0.00434	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—ATM—urinary bladder cancer	6.29e-05	0.00422	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDK4—urinary bladder cancer	6.26e-05	0.0042	CbGpPWpGaD
Metolazone—CA12—Metabolism—NAT2—urinary bladder cancer	6.01e-05	0.00403	CbGpPWpGaD
Metolazone—CA5A—Metabolism—RRM2—urinary bladder cancer	6e-05	0.00402	CbGpPWpGaD
Metolazone—CA9—Metabolism—CYP4B1—urinary bladder cancer	5.82e-05	0.0039	CbGpPWpGaD
Metolazone—CA5B—Metabolism—RRM2—urinary bladder cancer	5.6e-05	0.00376	CbGpPWpGaD
Metolazone—CA7—Metabolism—RRM2—urinary bladder cancer	5.6e-05	0.00376	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ENO2—urinary bladder cancer	5.55e-05	0.00373	CbGpPWpGaD
Metolazone—CA5A—Metabolism—HPGDS—urinary bladder cancer	5.55e-05	0.00373	CbGpPWpGaD
Metolazone—CA9—Metabolism—SLC19A1—urinary bladder cancer	5.5e-05	0.00369	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CREBBP—urinary bladder cancer	5.46e-05	0.00367	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—RB1—urinary bladder cancer	5.44e-05	0.00365	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTT1—urinary bladder cancer	5.39e-05	0.00361	CbGpPWpGaD
Metolazone—CA9—Metabolism—PRSS3—urinary bladder cancer	5.36e-05	0.00359	CbGpPWpGaD
Metolazone—CA4—Metabolism—TYMP—urinary bladder cancer	5.3e-05	0.00355	CbGpPWpGaD
Metolazone—CA12—Metabolism—RRM2—urinary bladder cancer	5.19e-05	0.00348	CbGpPWpGaD
Metolazone—CA7—Metabolism—HPGDS—urinary bladder cancer	5.19e-05	0.00348	CbGpPWpGaD
Metolazone—CA5B—Metabolism—HPGDS—urinary bladder cancer	5.19e-05	0.00348	CbGpPWpGaD
Metolazone—CA7—Metabolism—ENO2—urinary bladder cancer	5.19e-05	0.00348	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ENO2—urinary bladder cancer	5.19e-05	0.00348	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTT1—urinary bladder cancer	5.03e-05	0.00337	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTT1—urinary bladder cancer	5.03e-05	0.00337	CbGpPWpGaD
Metolazone—CA12—Metabolism—ENO2—urinary bladder cancer	4.8e-05	0.00322	CbGpPWpGaD
Metolazone—CA12—Metabolism—HPGDS—urinary bladder cancer	4.8e-05	0.00322	CbGpPWpGaD
Metolazone—CA4—Metabolism—NAT2—urinary bladder cancer	4.79e-05	0.00321	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDKN2A—urinary bladder cancer	4.79e-05	0.00321	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTT1—urinary bladder cancer	4.66e-05	0.00313	CbGpPWpGaD
Metolazone—CA5A—Metabolism—NQO1—urinary bladder cancer	4.48e-05	0.003	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CXCL8—urinary bladder cancer	4.34e-05	0.00291	CbGpPWpGaD
Metolazone—CA9—Metabolism—TYMP—urinary bladder cancer	4.28e-05	0.00287	CbGpPWpGaD
Metolazone—CA5B—Metabolism—NQO1—urinary bladder cancer	4.18e-05	0.0028	CbGpPWpGaD
Metolazone—CA7—Metabolism—NQO1—urinary bladder cancer	4.18e-05	0.0028	CbGpPWpGaD
Metolazone—CA4—Metabolism—RRM2—urinary bladder cancer	4.14e-05	0.00278	CbGpPWpGaD
Metolazone—SLC12A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.03e-05	0.00271	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—CDKN1A—urinary bladder cancer	3.91e-05	0.00262	CbGpPWpGaD
Metolazone—CA9—Metabolism—NAT2—urinary bladder cancer	3.87e-05	0.0026	CbGpPWpGaD
Metolazone—CA12—Metabolism—NQO1—urinary bladder cancer	3.87e-05	0.0026	CbGpPWpGaD
Metolazone—CA4—Metabolism—ENO2—urinary bladder cancer	3.83e-05	0.00257	CbGpPWpGaD
Metolazone—CA4—Metabolism—HPGDS—urinary bladder cancer	3.83e-05	0.00257	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTP1—urinary bladder cancer	3.73e-05	0.00251	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—EP300—urinary bladder cancer	3.72e-05	0.0025	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTT1—urinary bladder cancer	3.72e-05	0.00249	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTP1—urinary bladder cancer	3.49e-05	0.00234	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTP1—urinary bladder cancer	3.49e-05	0.00234	CbGpPWpGaD
Metolazone—CA5A—Metabolism—TYMS—urinary bladder cancer	3.47e-05	0.00233	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GSTM1—urinary bladder cancer	3.43e-05	0.0023	CbGpPWpGaD
Metolazone—CA5A—Metabolism—NCOR1—urinary bladder cancer	3.43e-05	0.0023	CbGpPWpGaD
Metolazone—CA9—Metabolism—RRM2—urinary bladder cancer	3.34e-05	0.00224	CbGpPWpGaD
Metolazone—CA5A—Metabolism—GPX1—urinary bladder cancer	3.29e-05	0.0022	CbGpPWpGaD
Metolazone—CA7—Metabolism—TYMS—urinary bladder cancer	3.24e-05	0.00217	CbGpPWpGaD
Metolazone—CA5B—Metabolism—TYMS—urinary bladder cancer	3.24e-05	0.00217	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTP1—urinary bladder cancer	3.23e-05	0.00217	CbGpPWpGaD
Metolazone—CA5A—Metabolism—ERCC2—urinary bladder cancer	3.23e-05	0.00216	CbGpPWpGaD
Metolazone—CA7—Metabolism—GSTM1—urinary bladder cancer	3.2e-05	0.00215	CbGpPWpGaD
Metolazone—CA7—Metabolism—NCOR1—urinary bladder cancer	3.2e-05	0.00215	CbGpPWpGaD
Metolazone—CA5B—Metabolism—NCOR1—urinary bladder cancer	3.2e-05	0.00215	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GSTM1—urinary bladder cancer	3.2e-05	0.00215	CbGpPWpGaD
Metolazone—CA9—Metabolism—HPGDS—urinary bladder cancer	3.1e-05	0.00208	CbGpPWpGaD
Metolazone—CA9—Metabolism—ENO2—urinary bladder cancer	3.1e-05	0.00208	CbGpPWpGaD
Metolazone—CA4—Metabolism—NQO1—urinary bladder cancer	3.09e-05	0.00207	CbGpPWpGaD
Metolazone—CA7—Metabolism—GPX1—urinary bladder cancer	3.07e-05	0.00206	CbGpPWpGaD
Metolazone—CA5B—Metabolism—GPX1—urinary bladder cancer	3.07e-05	0.00206	CbGpPWpGaD
Metolazone—CA5A—Metabolism—MTHFR—urinary bladder cancer	3.03e-05	0.00203	CbGpPWpGaD
Metolazone—CA5B—Metabolism—ERCC2—urinary bladder cancer	3.01e-05	0.00202	CbGpPWpGaD
Metolazone—CA7—Metabolism—ERCC2—urinary bladder cancer	3.01e-05	0.00202	CbGpPWpGaD
Metolazone—CA12—Metabolism—TYMS—urinary bladder cancer	3e-05	0.00201	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTT1—urinary bladder cancer	3e-05	0.00201	CbGpPWpGaD
Metolazone—CA12—Metabolism—NCOR1—urinary bladder cancer	2.97e-05	0.00199	CbGpPWpGaD
Metolazone—CA12—Metabolism—GSTM1—urinary bladder cancer	2.97e-05	0.00199	CbGpPWpGaD
Metolazone—CA12—Metabolism—GPX1—urinary bladder cancer	2.84e-05	0.00191	CbGpPWpGaD
Metolazone—CA5B—Metabolism—MTHFR—urinary bladder cancer	2.83e-05	0.0019	CbGpPWpGaD
Metolazone—CA7—Metabolism—MTHFR—urinary bladder cancer	2.83e-05	0.0019	CbGpPWpGaD
Metolazone—CA12—Metabolism—ERCC2—urinary bladder cancer	2.79e-05	0.00187	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TP53—urinary bladder cancer	2.66e-05	0.00179	CbGpPWpGaD
Metolazone—CA12—Metabolism—MTHFR—urinary bladder cancer	2.62e-05	0.00176	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTP1—urinary bladder cancer	2.58e-05	0.00173	CbGpPWpGaD
Metolazone—CA9—Metabolism—NQO1—urinary bladder cancer	2.5e-05	0.00167	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PPARG—urinary bladder cancer	2.46e-05	0.00165	CbGpPWpGaD
Metolazone—CA4—Metabolism—TYMS—urinary bladder cancer	2.39e-05	0.00161	CbGpPWpGaD
Metolazone—CA4—Metabolism—NCOR1—urinary bladder cancer	2.37e-05	0.00159	CbGpPWpGaD
Metolazone—CA4—Metabolism—GSTM1—urinary bladder cancer	2.37e-05	0.00159	CbGpPWpGaD
Metolazone—CA5A—Metabolism—CREBBP—urinary bladder cancer	2.36e-05	0.00158	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PPARG—urinary bladder cancer	2.3e-05	0.00154	CbGpPWpGaD
Metolazone—CA7—Metabolism—PPARG—urinary bladder cancer	2.3e-05	0.00154	CbGpPWpGaD
Metolazone—CA4—Metabolism—GPX1—urinary bladder cancer	2.27e-05	0.00152	CbGpPWpGaD
Metolazone—CA4—Metabolism—ERCC2—urinary bladder cancer	2.23e-05	0.00149	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CREBBP—urinary bladder cancer	2.21e-05	0.00148	CbGpPWpGaD
Metolazone—CA7—Metabolism—CREBBP—urinary bladder cancer	2.21e-05	0.00148	CbGpPWpGaD
Metolazone—CA12—Metabolism—PPARG—urinary bladder cancer	2.13e-05	0.00143	CbGpPWpGaD
Metolazone—CA4—Metabolism—MTHFR—urinary bladder cancer	2.09e-05	0.0014	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTP1—urinary bladder cancer	2.08e-05	0.0014	CbGpPWpGaD
Metolazone—CA12—Metabolism—CREBBP—urinary bladder cancer	2.04e-05	0.00137	CbGpPWpGaD
Metolazone—CA9—Metabolism—TYMS—urinary bladder cancer	1.93e-05	0.0013	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTGS2—urinary bladder cancer	1.93e-05	0.0013	CbGpPWpGaD
Metolazone—CA9—Metabolism—GSTM1—urinary bladder cancer	1.91e-05	0.00128	CbGpPWpGaD
Metolazone—CA9—Metabolism—NCOR1—urinary bladder cancer	1.91e-05	0.00128	CbGpPWpGaD
Metolazone—CA9—Metabolism—GPX1—urinary bladder cancer	1.83e-05	0.00123	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTGS2—urinary bladder cancer	1.81e-05	0.00121	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTGS2—urinary bladder cancer	1.81e-05	0.00121	CbGpPWpGaD
Metolazone—CA9—Metabolism—ERCC2—urinary bladder cancer	1.8e-05	0.00121	CbGpPWpGaD
Metolazone—CA4—Metabolism—PPARG—urinary bladder cancer	1.7e-05	0.00114	CbGpPWpGaD
Metolazone—CA9—Metabolism—MTHFR—urinary bladder cancer	1.69e-05	0.00113	CbGpPWpGaD
Metolazone—CA5A—Metabolism—PTEN—urinary bladder cancer	1.69e-05	0.00113	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTGS2—urinary bladder cancer	1.67e-05	0.00112	CbGpPWpGaD
Metolazone—CA4—Metabolism—CREBBP—urinary bladder cancer	1.63e-05	0.00109	CbGpPWpGaD
Metolazone—CA5A—Metabolism—EP300—urinary bladder cancer	1.61e-05	0.00108	CbGpPWpGaD
Metolazone—CA5B—Metabolism—PTEN—urinary bladder cancer	1.57e-05	0.00106	CbGpPWpGaD
Metolazone—CA7—Metabolism—PTEN—urinary bladder cancer	1.57e-05	0.00106	CbGpPWpGaD
Metolazone—CA5B—Metabolism—EP300—urinary bladder cancer	1.5e-05	0.00101	CbGpPWpGaD
Metolazone—CA7—Metabolism—EP300—urinary bladder cancer	1.5e-05	0.00101	CbGpPWpGaD
Metolazone—CA12—Metabolism—PTEN—urinary bladder cancer	1.46e-05	0.000979	CbGpPWpGaD
Metolazone—CA12—Metabolism—EP300—urinary bladder cancer	1.39e-05	0.000934	CbGpPWpGaD
Metolazone—CA9—Metabolism—PPARG—urinary bladder cancer	1.37e-05	0.000919	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTGS2—urinary bladder cancer	1.33e-05	0.000895	CbGpPWpGaD
Metolazone—CA9—Metabolism—CREBBP—urinary bladder cancer	1.32e-05	0.000883	CbGpPWpGaD
Metolazone—CA4—Metabolism—PTEN—urinary bladder cancer	1.16e-05	0.000781	CbGpPWpGaD
Metolazone—CA4—Metabolism—EP300—urinary bladder cancer	1.11e-05	0.000744	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTGS2—urinary bladder cancer	1.08e-05	0.000723	CbGpPWpGaD
Metolazone—CA9—Metabolism—PTEN—urinary bladder cancer	9.4e-06	0.000631	CbGpPWpGaD
Metolazone—CA9—Metabolism—EP300—urinary bladder cancer	8.97e-06	0.000602	CbGpPWpGaD
